Group 1: Company Strategy and Development - The company's development strategy focuses on leveraging comparative advantages to create two profitable platforms: pharmaceutical production and medical services, aiming for both to achieve equal profitability within 3-5 years [2] - The acquisition of Anqing Hospital is progressing, with the company actively negotiating with local government and stakeholders [2][3] - The company has no current plans for incentives for the core management team of the hospitals [3] Group 2: Hospital Acquisition and Market Overview - Anqing Hospital is undergoing restructuring, and the company is in discussions regarding the acquisition of its equity [2] - The company plans to invest no more than 140 million RMB to acquire the controlling stake in Anqing Petrochemical Hospital, which has 562 operational beds and specializes in burn and plastic surgery [7][9] - Anqing City has a population of 6.2 million, with an average annual disposable income of over 22,200 RMB for urban residents [6] Group 3: Operational Insights and Future Plans - The company currently operates two hospitals and recognizes the need to focus on developing a professional talent pool for sustainable growth [4] - The company has no specific timeline or quantity planning for future hospital layouts [3] - The company is committed to both expanding its main business through acquisitions and considering divestment of underperforming assets [10] Group 4: Financial Performance and Hospital Metrics - Nanjing Drum Tower Hospital, affiliated with Nanjing University Medical School, has 2,500 beds and served over 2.6 million outpatient visits in 2013 [8] - Anqing Hospital has 29 clinical and medical technology departments, with key specialties in burn and plastic surgery, as well as nephrology and otolaryngology [6][7]

Financial Performance - The company's operating revenue for Q3 2022 was ¥701,676,933.27, representing a year-on-year increase of 1.87%[5]. - Net profit attributable to shareholders for the same period was ¥33,735,225.06, a significant increase of 56.47% compared to the previous year[5]. - The basic earnings per share for Q3 2022 was ¥0.0661, up by 54.47% year-on-year[5]. - Total operating revenue for the current period is ¥2,053,856,118.01, a decrease of 2.7% from ¥2,111,013,131.98 in the previous period[23]. - Net profit for the current period is ¥105,406,239.67, a decrease of 14.0% compared to ¥122,756,762.52 in the previous period[24]. - Basic and diluted earnings per share for the current period are both ¥0.1826, down from ¥0.1935 in the previous period[25]. - Total comprehensive income for the current period is ¥119,568,574.16, slightly down from ¥122,756,762.52 in the previous period[25]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,558,330,945.72, reflecting a 2.49% increase from the end of the previous year[5]. - As of September 30, 2022, the total assets of Jinling Pharmaceutical Co., Ltd. amounted to CNY 4,558,330,945.72, an increase from CNY 4,447,665,260.23 at the beginning of the year[21]. - The company's current assets totaled CNY 2,395,433,878.20, compared to CNY 2,288,834,000.04 at the start of the year, reflecting a growth of approximately 4.65%[20]. - The total liabilities stood at CNY 909,166,026.93, slightly down from CNY 913,096,006.32 at the beginning of the year[21]. - The equity attributable to shareholders of the parent company increased to CNY 3,007,413,799.43 from CNY 2,927,728,885.61, marking an increase of about 2.72%[21]. Cash Flow - The company's cash flow from operating activities decreased by 32.74% year-on-year, totaling ¥141,229,553.92[5][13]. - The net cash flow from operating activities for Q3 2022 was ¥141,229,553.92, a decrease of 32.8% compared to ¥209,965,324.74 in Q3 2021[27]. - The total cash and cash equivalents at the end of Q3 2022 stood at ¥1,122,269,631.54, an increase from ¥1,020,710,012.97 in Q3 2021[27]. - The company reported a total cash outflow from operating activities of ¥1,925,915,764.21, which is an increase from ¥1,879,745,650.11 in Q3 2021[27]. - Cash inflow from financing activities totaled ¥29,272,880.00, up from ¥15,000,000.00 in Q3 2021[27]. - The net cash flow from financing activities was -¥46,078,805.56, compared to -¥38,031,678.88 in the previous year[27]. Expenses and Income - The company's goodwill increased by 72.59% due to the acquisition of a 65.00% stake in Chizhou Dongsheng Pharmaceutical Co., Ltd.[9]. - Non-operating income for the year increased by 147.86% due to higher government subsidies received[11]. - Investment income decreased by 54.02% year-on-year, primarily due to the absence of performance compensation from subsidiaries[12]. - The company reported a 36.00% decrease in income tax expenses compared to the previous year, attributed to a reduction in taxable income[13]. - Research and development expenses increased to ¥45,168,326.22, up 14.5% from ¥39,351,727.41 in the previous period[24]. - Cash received from sales of goods and services is ¥2,041,251,922.89, a decrease of 1.0% from ¥2,061,084,625.63 in the previous period[26]. - Other income for the current period is ¥7,781,011.80, an increase from ¥3,139,232.80 in the previous period[24]. - Investment income for the current period is ¥10,752,550.99, down from ¥23,385,821.36 in the previous period[24]. Inventory and Receivables - Accounts receivable increased to CNY 409,019,830.84 from CNY 320,639,675.01, representing a rise of about 27.5%[20]. - The company reported a decrease in inventory to CNY 226,891,654.63 from CNY 245,476,356.41, a reduction of approximately 7.5%[20]. Other Information - The company has not reported any new product launches or technological advancements in this quarter[20]. - There are no significant updates regarding market expansion or mergers and acquisitions mentioned in the report[20]. - The company continues to utilize idle funds for wealth management products, as indicated in previous announcements[17].

Share Capital and Dividends - Jinling Pharmaceutical's total shares increased from 504 million to 510.4 million after the completion of the restricted stock incentive plan in February 2022[22]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company completed the grant registration of 6.4 million restricted stocks to 72 incentive objects at a grant price of 3.69 CNY per share[82]. - The company received approval from the Nanjing State-owned Assets Supervision and Administration Commission for its 2021 restricted stock incentive plan[81]. - The company issued 6.4 million A-shares at a price of 3.69 RMB per share on January 17, 2022, with the shares listed on February 16, 2022[130]. - A total of 72 incentive recipients were granted 6.4 million restricted shares under the 2021 Restricted Stock Incentive Plan, with the grant date set on January 27, 2022[132]. Financial Performance - The company's total revenue for the reporting period was CNY 1,352,179,184.74, a decrease of 4.92% compared to the same period last year[23]. - Net profit attributable to shareholders was CNY 59,211,354.27, down 22.05% year-over-year[23]. - The net cash flow from operating activities was CNY 413,347.66, a significant decline of 99.75% compared to the previous year[23]. - Basic and diluted earnings per share were both CNY 0.1165, reflecting a decrease of 22.69% from the prior year[23]. - The company's total operating revenue for the reporting period was ¥1,352,179,184.74, representing a decrease of 4.92% compared to ¥1,422,221,213.81 in the same period last year[46]. - The total profit for the first half of 2022 was CNY 83,347,790.98, a decline of 31.4% from CNY 121,495,799.91 in the previous year[156]. - The company reported a net profit margin of approximately 6.5% for the first half of 2022, down from 8.9% in the same period of 2021[155]. - The company achieved a net profit of CNY 68,180,188.34, a decrease of 27.5% compared to CNY 93,889,092.81 in the first half of 2021[156]. Assets and Liabilities - The company's total assets increased by 1.27% to CNY 4,503,977,145.82 compared to the end of the previous year[23]. - The net assets attributable to shareholders rose by 1.57% to CNY 2,973,678,574.37[23]. - Cash and cash equivalents decreased to ¥1,078,057,736.57, accounting for 23.94% of total assets, down 9.83% from the previous year due to subsidiary investments[52]. - Accounts receivable increased to ¥387,359,636.38, representing 8.60% of total assets, up 1.39% from the previous year[52]. - Total liabilities decreased to CNY 887,027,567.38 from CNY 913,096,006.32, indicating a reduction of about 2.9%[150]. - The total assets at the end of the reporting period amounted to 510.4 million yuan, with total liabilities of 483.4 million yuan[176]. Research and Development - The company invested CNY 20.0975 million in research and development during the reporting period[41]. - Research and development expenses amounted to ¥20,097,465.06, down 11.49% from ¥22,707,636.56 in the previous year[46]. - The company is cautious about R&D risks associated with new drug development and is optimizing its R&D strategy[73]. - The R&D expenses for the period were 380 million, accounting for approximately 11.6% of total revenue[168]. - Research and development expenses for the first half of 2022 were 2.9 million yuan, which is a 4.3% increase from the previous year[169]. Market Position and Strategy - The company maintained its focus on pharmaceutical manufacturing and healthcare services, with key products including Suplife and Pilex[32][33]. - The company is positioned in a strategic industry that is crucial for national health and economic development, with a strong reputation in the pharmaceutical sector[35]. - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[155]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[167]. - The company is exploring potential acquisitions to enhance its product portfolio and market position[167]. Risk Management - The report emphasizes the importance of risk awareness regarding industry policy changes and market competition risks[3]. - The company is committed to risk management, implementing a dual prevention mechanism for risk control[39]. - The company is facing risks from industry policy changes, including drug approval and price control measures, and plans to adapt its business model accordingly[70]. Environmental and Social Responsibility - The company is focusing on improving its environmental management systems to comply with stricter regulations in the pharmaceutical industry[72]. - The company has implemented two wastewater treatment facilities with capacities of 1200 m³/d and 800 m³/d, ensuring that treated wastewater meets discharge standards[85]. - The company’s environmental monitoring results indicate that all pollutants are discharged within the standards[88]. - The company organized 178 personnel to assist in COVID-19 testing, completing 1.1 million tests across various cities[38]. - The company actively supports rural revitalization projects, achieving sales revenue of 330,000 CNY and a profit of 130,000 CNY from the honeysuckle tea project from January to June 2022[92]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting heads[3]. - The report indicates that all board members attended the meeting to review the report, ensuring collective responsibility for its contents[3]. - The company has revised its articles of association and related governance rules as part of its corporate governance improvements[119]. - The company follows the accounting standards set by the Ministry of Finance, ensuring that its financial statements reflect its financial position accurately[193]. Legal and Compliance - The company is currently involved in a lawsuit seeking 1,772.32 million RMB related to a share transfer dispute, which is still under review[102]. - The company has not reported any major litigation or arbitration matters during the reporting period[102]. - There are no violations regarding external guarantees reported during the period[99]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[90].

Financial Performance - The company's operating revenue for Q1 2022 was ¥693,016,544.54, a decrease of 1.22% compared to ¥701,603,298.78 in the same period last year[3] - Net profit attributable to shareholders increased by 12.12% to ¥39,240,141.55 from ¥34,999,569.83 year-on-year[3] - Net profit for the current period is ¥44,443,693.56, an increase of 4.4% compared to ¥42,567,636.65 in the previous period[21] - Operating profit for the current period is ¥54,849,544.06, slightly down from ¥56,428,216.74, a decrease of 2.8%[21] - Basic earnings per share increased to ¥0.0769 from ¥0.0694, reflecting a growth of 7.2%[22] Cash Flow - The net cash flow from operating activities decreased significantly by 451.37%, resulting in a negative cash flow of ¥72,458,661.05 compared to a positive cash flow of ¥20,621,729.67 in the previous year[3] - Cash flow from operating activities shows a net outflow of ¥72,458,661.05, compared to a net inflow of ¥20,621,729.67 in the previous period[25] - Cash flow from investment activities resulted in a net outflow of ¥460,424,469.27, worsening from a net outflow of ¥269,446,173.11 in the previous period[25] - The net cash flow from financing activities was 8,534,333.34, compared to a negative cash flow of -67,000.00 in the previous year[26] - The total cash inflow from financing activities was ¥23,616,000.00, with no previous inflow recorded[25] - The total cash and cash equivalents at the end of the period decreased to 957,243,394.73 from 1,049,446,008.63 year-over-year[26] - The net increase in cash and cash equivalents was -524,349,156.37, compared to -248,891,096.60 in the same period last year[26] - The cash flow out from financing activities totaled 15,081,666.66, compared to 67,000.00 in the previous year[26] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,440,343,153.87, a slight decrease of 0.16% from the previous year-end[3] - The company's cash and cash equivalents decreased to RMB 976,861,077.66 from RMB 1,501,760,713.59, representing a decline of approximately 34.8%[16] - Accounts receivable increased to RMB 410,485,224.32 from RMB 320,639,675.01, reflecting a growth of about 28.0%[16] - The company's inventory stood at RMB 246,328,627.03, showing a marginal increase from RMB 245,476,356.41[16] - Total liabilities decreased to RMB 837,714,206.40 from RMB 913,096,006.32, indicating a reduction of approximately 8.2%[19] - The equity attributable to shareholders of the parent company increased to RMB 2,990,585,027.16 from RMB 2,927,728,885.61, marking an increase of about 2.1%[19] Investments and Expenses - Research and development expenses rose by 37.13% compared to the same period last year, indicating increased investment in innovation[8] - Research and development expenses increased to ¥9,516,114.99, up 37% from ¥6,939,640.95 in the previous period[21] - The company's investment income decreased by 83.63% year-on-year, attributed to reduced gains from long-term equity investments[9] - The company's prepayments increased by 136.84% compared to the beginning of the year, reflecting a rise in procurement activities[7] - The company's intangible assets increased by 81.21% compared to the beginning of the year, mainly due to the acquisition of land use rights[7] - The company completed the registration of its 2021 restricted stock incentive plan, increasing its registered capital by RMB 6,400,000 to RMB 510,400,000[13] - Jinling Pharmaceutical's subsidiary acquired land use rights for a plot in Hefei, indicating ongoing expansion efforts[13] - The company successfully completed the acquisition of a stake in Chizhou Dongsheng Pharmaceutical Co., Ltd., enhancing its investment portfolio[13] - The company's intangible assets rose significantly to RMB 254,047,202.33 from RMB 140,196,138.05, reflecting an increase of approximately 81.0%[18] Other Information - The company's weighted average return on equity increased to 1.33% from 1.22% year-on-year[3] - The first quarter report was not audited[27] - The company did not pay dividends or profits to minority shareholders during the first quarter[26]

Financial Performance - The company's operating revenue for 2021 was ¥2,808,754,876.16, representing a 12.18% increase compared to ¥2,503,732,374.15 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥120,625,946.04, an increase of 85.19% from ¥65,136,495.93 in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 15.53% to ¥72,159,809.38 in 2021 from ¥85,427,396.25 in 2020[21]. - The basic earnings per share for 2021 was ¥0.2393, up 85.22% from ¥0.1292 in 2020[21]. - The total assets at the end of 2021 were ¥4,447,665,260.23, a 3.83% increase from ¥4,283,570,372.62 at the end of 2020[22]. - The net assets attributable to shareholders at the end of 2021 were ¥2,927,728,885.61, reflecting a 2.46% increase from ¥2,857,463,167.29 at the end of 2020[22]. - The net cash flow from operating activities for 2021 was ¥292,026,282.03, a decrease of 6.24% from ¥311,464,432.11 in 2020[21]. - The company reported non-recurring gains of ¥53,131,553.79 from the disposal of non-current assets in 2021, compared to a loss of ¥1,581,888.97 in 2020[26]. - The weighted average return on equity for 2021 was 4.16%, an increase of 1.90% from 2.26% in 2020[21]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares (including tax) based on a total share capital of 510,400,000 as of March 25, 2022[6]. - The total amount of cash dividends distributed accounted for 100% of the available profits for distribution[144]. - The cash dividend per 10 shares is CNY 1.00 (including tax), based on a total share capital of 510,400,000 shares[144]. - The company maintained a complete decision-making process for its cash dividend policy, ensuring the rights of minority shareholders were protected[144]. Risks and Challenges - The company acknowledges risks including industry policy changes, operational risks due to the COVID-19 pandemic, and market competition risks[6]. - The company faces risks from industry policy changes, including drug approval and price control measures, which may impact future growth[92]. - The company is addressing the risk of raw material price fluctuations by optimizing procurement processes and maintaining reserves of commonly used raw materials[93]. - The company is committed to improving research and development capabilities to mitigate risks associated with new drug development and market acceptance[94]. Market and Industry Insights - The pharmaceutical industry in China is projected to grow significantly, driven by increased healthcare awareness and rising demand for medications, with total healthcare expenditure expected to reach CNY 7.23 trillion in 2020[1]. - The healthcare market in China is expected to maintain rapid growth due to economic development, population growth, and increasing health awareness among residents[3]. - The aging population in China is substantial, with 264.02 million individuals aged 60 and above, representing 18.7% of the total population, indicating a growing market for healthcare services[2]. - In 2021, the total number of medical visits in China reached 6.05 billion, a year-on-year increase of 22.4%, with public hospitals accounting for 3.22 billion visits, up 28.3%[3]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[5]. - The company has established a strong governance structure with independent directors to ensure compliance and strategic oversight[112][115]. - The company maintains independent operations from its controlling shareholder, ensuring no infringement on the rights of other shareholders[100]. - The company has a clear governance structure that operates independently from its controlling shareholder, ensuring no hierarchical relationship exists[103]. Research and Development - The company invested CNY 57.0147 million in research and development during the reporting period[50]. - The company holds 14 patent applications, including 3 invention patents and 11 utility model patents, with 18 patents granted[50]. - The company is actively pursuing new product development and has made progress in secondary development of existing products, including obtaining a patent for a detection method[50]. - The company has filed 103 research projects, with 20 approved, including 6 at the national level[50]. Social Responsibility - The company participated in 30 public welfare volunteer activities in 2021, investing a total of RMB 1.58 million, including RMB 1.4 million for pandemic relief efforts[162]. - In 2021, the company allocated RMB 180,000 for poverty alleviation initiatives, including RMB 120,000 for healthcare support and RMB 42,000 for educational assistance to 99 impoverished students[164]. - The company has committed to corporate social responsibility by integrating public welfare support into its annual budget[163]. - The company has actively engaged in industry poverty alleviation projects, including donations for community health and education initiatives[164]. Environmental Compliance - The company has implemented wastewater treatment facilities with capacities of 1200m³/d and 800m³/d, ensuring compliance with environmental standards[157]. - The company achieved a total COD discharge of 26.38 tons, which is below the regulatory limits, demonstrating effective pollution control measures[157]. - The company maintains a pollution discharge permit, with all emissions compliant with the permit requirements[158]. - The company conducted an environmental self-monitoring program, confirming that all pollutant emissions met standards during the reporting period[160]. Employee and Management - The total number of employees at the end of the reporting period was 4,865, with 906 in the parent company and 3,959 in major subsidiaries[138]. - The company had 3,430 technical personnel, representing approximately 70.5% of the total workforce[138]. - The training budget for 2021 was set at 5.8535 million yuan, with over 80% of the annual training plan achieved[141]. - The company implemented a competitive salary policy to enhance employee motivation and has established a dual career development channel[140]. Future Outlook - In 2022, the company plans to focus on strengthening technological innovation and enhancing the transformation of innovative achievements[91]. - The company aims to accelerate digital transformation to cultivate new growth drivers for development[91]. - Future guidance indicates a cautious optimism for revenue growth, contingent on market conditions and successful product development[110]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[121].

金陵药业股份有限公司 2021 年第三季度报告 证券代码：000919 证券简称：金陵药业 公告编号：2021-056 金陵药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 √ 适用 □ 不适用 1 金陵药业股份有限公司 2021 年第三季度报告 单位：元 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 688,791,918. ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,422,221,213.81, representing a 24.41% increase compared to CNY 1,143,200,873.29 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached CNY 75,957,082.73, a significant increase of 211.64% from CNY 24,373,296.85 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 85,326,124.05, up 64.68% from CNY 51,812,897.76 year-on-year[22]. - The net cash flow from operating activities was CNY 164,927,320.35, showing a remarkable increase of 310.15% compared to CNY 40,211,934.86 in the same period last year[22]. - The basic earnings per share for the first half of 2021 was CNY 0.1507, which is a 211.36% increase from CNY 0.0484 in the previous year[22]. - The total operating revenue for the first half of 2021 was CNY 1,422,221,213.81, an increase of 24.4% compared to CNY 1,143,200,873.29 in the first half of 2020[138]. - The total operating costs for the first half of 2021 were CNY 1,295,044,203.65, up from CNY 1,064,977,269.47 in the same period last year, reflecting a growth of 21.6%[138]. - The net profit attributable to the parent company for the first half of 2021 was CNY 127,177,010.16, compared to CNY 78,223,603.82 in the first half of 2020, representing an increase of 62.5%[138]. - The company's total profit for the first half of 2021 was CNY 121,495,799.91, compared to CNY 48,070,775.75 in the previous year, marking an increase of 152.5%[143]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 4,421,670,305.33, reflecting a 3.22% increase from CNY 4,283,570,372.62 at the end of the previous year[22]. - The total liabilities increased to CNY 946,211,128.38 as of June 30, 2021, compared to CNY 850,425,124.64 at the end of 2020, marking an increase of 11.3%[133]. - The company's total assets as of June 30, 2021, amounted to CNY 4,421,670,305.33, up from CNY 4,283,570,372.62 at the end of 2020[133]. - The company's cash and cash equivalents decreased by 6.35% to CNY 1,077.62 million, down from CNY 1,315.72 million at the end of the previous year[54]. - The company's long-term equity investments were valued at 267,461,814.12 yuan, slightly up from 266,808,210.54 yuan[131]. Research and Development - In the first half of 2021, the company invested CNY 22.71 million in research and development, with a focus on advancing projects through the registration process[41]. - Research and development investment increased by 15.90% to CNY 22,707,636.56 compared to CNY 19,592,299.58 in the previous year[46]. - The company's R&D expenses for the first half of 2021 were CNY 22,707,636.56, compared to CNY 19,592,299.58 in the same period last year, reflecting an increase of 10.8%[138]. - The company has submitted 15 projects for the 2021 National Natural Science Foundation, indicating a strong commitment to scientific research[41]. Market and Industry Position - The company operates in a favorable industry environment, with the domestic pharmaceutical industry experiencing rapid growth driven by an aging population and increased health awareness[33]. - The company is positioned well within the industry, benefiting from a large population base and ongoing healthcare reforms in China[34]. - The company aims to strengthen its dual-platform development in pharmaceuticals and healthcare, leveraging national policies to enhance market positioning[36]. - The company has set a strategic direction for the "14th Five-Year Plan," focusing on innovation-driven development and enhancing efficiency through scale[36]. - The company has actively engaged in market research and developed marketing strategies to maintain its competitive edge in the blood supplement sector[38]. Risks and Challenges - The company faces risks including industry policy changes, operational risks due to the COVID-19 pandemic, and market competition risks[6]. - The company faces risks from industry policy changes, including drug approval and price control measures, which could significantly impact future development[65]. - The ongoing global pandemic poses operational risks, with potential adverse effects on company performance if the situation does not improve[66]. - Fluctuations in raw material prices could increase procurement costs, potentially squeezing profit margins and affecting overall performance[66]. Environmental and Social Responsibility - The company has established a strict quality control system, with no major product quality incidents reported to date, but remains vigilant against potential risks[67]. - Environmental protection compliance is critical, with the company classified as a key pollutant discharge unit, necessitating adherence to stringent regulations[76]. - The company has implemented a "rainwater and sewage diversion" system to manage wastewater effectively, ensuring compliance with environmental standards[77]. - The company has invested RMB 115,000 in social responsibility initiatives, focusing on health, education, and industry support[81]. - In health poverty alleviation, the company provided free clinical guidance and training to local healthcare workers, enhancing medical management[81]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The total number of shares outstanding remained at 504 million, with a slight adjustment in the structure due to management changes[113]. - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 45.23% of the shares, totaling 227,943,839 shares[115]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[88]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 10% to 15%[183]. - New product launches are expected to contribute an additional 5% to revenue growth in the upcoming quarters[183]. - The company is focusing on market expansion, targeting a 30% increase in market share in the next fiscal year[183]. - The company plans to continue expanding its market presence and investing in new product development[155].

金陵药业股份有限公司 2021 年第一季度报告全文 金陵药业股份有限公司 2021 年第一季度报告 2021-029 2021 年 04 月 1 金陵药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁玉堂、主管会计工作负责人陈亚军及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 701,603,298.78 | 513,804,171.32 | 36.55% | | 归属于上市公司股东的净利润（元） | 34,999,569.83 | -27,613 ...

Financial Performance - The company reported a total revenue of 504 million CNY for the year 2020, with a year-on-year growth of 10%[6] - The company's operating revenue for 2020 was ¥2,503,732,374.15, a decrease of 1.23% compared to ¥2,534,920,539.72 in 2019[6] - The net profit attributable to shareholders was ¥65,136,495.93, representing a significant decline of 55.18% from ¥145,319,439.10 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥85,427,396.25, an increase of 102.30% compared to ¥42,228,340.42 in 2019[6] - The net cash flow from operating activities decreased by 33.14% to ¥311,464,432.11 from ¥465,847,095.18 in 2019[6] - The total assets at the end of 2020 were ¥4,283,570,372.62, reflecting a 3.01% increase from ¥4,158,340,176.15 at the end of 2019[6] - The company reported a weighted average return on equity of 2.26%, down from 5.08% in 2019, indicating a decline in profitability[6] - The company achieved total operating revenue of 250,373.24 million yuan and a net profit attributable to shareholders of 6,513.65 million yuan during the reporting period[37] - Total revenue for 2020 was ¥2,503,732,374.15, a decrease of 1.23% compared to ¥2,534,920,539.72 in 2019[47] - Revenue from pharmaceutical production and sales was ¥1,345,378,717.03, accounting for 53.73% of total revenue, down 1.89% from the previous year[47] - Revenue from medical services was ¥1,123,082,965.40, representing 44.86% of total revenue, a decrease of 1.27% year-over-year[47] Dividend and Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 1 CNY per 10 shares, totaling 50.4 million CNY[6] - In 2020, the company proposed a cash dividend of CNY 1.00 per share, totaling CNY 50,400,000, which represents 77.38% of the distributable profit[89][92] - The company's net profit for 2020 was CNY 46,366,647.92, with a distributable profit of CNY 785,313,845.82 at year-end[92] Market and Business Strategy - The company plans to continue expanding its market presence and invest in new product development to enhance its competitive edge[6] - The company is focused on expanding its pharmaceutical and healthcare service platforms to adapt to changing market conditions[37] - The company launched new products such as "Yihua" series honeysuckle tea and Dendrobium flower tea, laying a foundation for expanding the health product line[40] - The company is currently advancing several R&D projects, including the development of new drugs and improvements to existing products[59] - The company plans to focus on the "14th Five-Year Plan" strategy, emphasizing the dual-platform strategy of "pharmaceuticals and health care" for deeper integration[82] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential deals[166] Operational Challenges and Compliance - The company emphasized the importance of maintaining compliance with industry regulations and managing risks related to market competition and raw material price fluctuations[6] - The company did not report any significant changes in its business, management, or operational models compared to the previous year[29] - The company has not reported any changes in its main business operations or major shareholders during the reporting period[18] - The company has not engaged in any significant equity investments during the reporting period[74] - The company has not reported any significant changes in its financial indicators due to the share changes[141] Research and Development - Research and development expenses for the year were ¥43,709,428.30, a slight decrease of 0.47% compared to ¥43,915,066.29 in 2019[59] - The proportion of R&D expenses to operating income increased to 1.75% from 1.73% in the previous year[62] - The company has made significant progress in its consistency evaluation projects, with major milestones achieved during the reporting period[61] - The company is investing 50 million yuan in R&D for new technologies aimed at improving production efficiency[166] Social Responsibility and Community Engagement - The company invested a total of 719,400 CNY in poverty alleviation efforts, including 42,000 CNY for industrial development projects and 46,000 CNY for educational support[128] - The company supported 99 impoverished students with a total funding of 46,000 CNY in 2020, continuing its commitment to educational assistance[128] - The company provided 42,000 CNY for health poverty alleviation, including support for local healthcare facilities and free medical services[128] - The company has been recognized for its contributions to social responsibility, including awards for blood donation efforts[128] - The company plans to continue its poverty alleviation initiatives in 2021, focusing on community engagement and healthcare support[130] Governance and Management - The company has undergone a change in its board of directors and senior management during the reporting period[134] - The company has a total of 9 board members, with 5 currently in office and 4 independent directors[155] - The average age of the current board members is approximately 50 years[155] - The company has a diverse management team with backgrounds in economics, pharmacy, and engineering, enhancing its operational capabilities[161] - The company is focused on maintaining stability in its leadership and shareholding structure[156] - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring compliance with tax regulations[188] Shareholder Information - The company reported a total share count of 504,000,000, with 99.75% being unrestricted shares and 0.25% being restricted shares[139] - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 45.23% of the shares, totaling 227,943,839 shares[142] - The actual controller of the company is the Nanjing Municipal Government State-owned Assets Supervision and Administration Commission, which has not changed during the reporting period[147] - The total shares held by the board members at the end of the period increased to 1,019,736 shares, with an increase of 30,000 shares during the period[156] Environmental Compliance - The company has established two wastewater treatment systems with a daily processing capacity of 2,000 m³, ensuring compliance with environmental standards[131] - The company has implemented a comprehensive environmental monitoring program to ensure compliance with pollution discharge standards[132]

Financial Performance - Operating revenue for the reporting period was ¥675,236,157.77, representing a year-on-year increase of 3.75%[8] - Net profit attributable to shareholders was ¥53,228,127.19, a significant increase of 480.70% compared to the same period last year[8] - Basic earnings per share for the reporting period was ¥0.1056, reflecting an increase of 480.22% year-on-year[8] - The net cash flow from operating activities was ¥127,280,889.71, up 95.47% compared to the same period last year[8] - Other income increased by 47.60% year-on-year, primarily due to an increase in government subsidies received[17] - The total comprehensive income attributable to the parent company was CNY 53,228,127.19, compared to CNY 9,166,178.96 in the previous period[48] - The net profit for Q3 2020 reached CNY 61,537,775.88, compared to CNY 22,099,148.18 in the same period last year, representing a significant increase[47] - The net profit for the current period is CNY 29,543,348.43, a significant decrease of 83.1% from CNY 175,100,343.54 in the previous period[60] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,188,614,207.05, an increase of 0.73% compared to the end of the previous year[8] - The company reported a decrease of 0.28% in net assets attributable to shareholders compared to the end of the previous year, totaling ¥2,869,928,095.40[8] - The total current assets as of September 30, 2020, amounted to ¥2,293,023,983.62, an increase from ¥2,245,948,685.77 at the end of 2019[37] - The total liabilities as of September 30, 2020, were ¥749,024,311.01, up from ¥733,622,631.91 at the end of 2019[39] - The total equity attributable to shareholders of the parent company was CNY 2,121,836,899.31, down from CNY 2,177,973,550.88[43] - Total liabilities reached CNY 733,622,631.91, indicating a stable financial position[72] - Total current liabilities amounted to CNY 677,336,636.22, with accounts payable at CNY 304,355,023.23[71] Cash Flow - The net cash flow from operating activities decreased by 44.80% year-on-year, mainly due to a reduction in cash received from sales of goods and services[17] - The total cash inflow from operating activities is CNY 1,827,913,724.56, down from CNY 2,010,386,337.59 in the previous period[63] - The total cash outflow from operating activities is CNY 1,660,420,899.99, a decrease from CNY 1,706,951,291.68 in the previous period[63] - Operating cash flow for the period was ¥90,399,321.35, a decrease of 50.2% compared to ¥181,590,512.03 in the previous period[65] - Cash inflow from operating activities totaled ¥507,379,386.68, down 14.5% from ¥593,878,207.11 in the previous period[65] Shareholder Information - The total number of shareholders at the end of the reporting period was 29,270[12] - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., held 45.23% of the shares[12] Investment and Expenses - Research and development expenses for Q3 2020 were CNY 9,288,818.88, slightly down from CNY 10,747,801.49 in the previous period[46] - Research and development expenses increased to CNY 28,881,118.46, up 5.2% from CNY 27,462,004.47 in the previous period[58] - The company reported an investment income of CNY 14,103,555.82, significantly higher than CNY 5,038,657.79 in the previous period[46] - The company reported a significant decline in investment income, with CNY 17,150,807.34 compared to CNY 21,370,654.18 in the previous period[58] Other Financial Metrics - The weighted average return on net assets was 1.89%, a decrease of 1.58% compared to the previous year[8] - The company reported a 3241.28% increase in credit impairment losses year-on-year, primarily due to an increase in bad debt provisions[17] - The company has ongoing litigation regarding contract disputes, which may impact future operations[18] - The company has no significant contracts or major liabilities that could impact future performance[29] - There were no non-operating fund occupations by controlling shareholders during the reporting period[31]